PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
3.54%
G&A change of 3.54% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
-10.44%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-10.44%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
721.68%
D&A growth exceeding 1.5x Biotechnology median of 1.00%. Jim Chanos would check for overinvestment.
11.90%
EBITDA change of 11.90% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Income change of 10.44% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
10.28%
Income change of 10.28% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Income change of 10.28% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS change of 12.12% versus flat Biotechnology. Walter Schloss would verify quality.
10.49%
Diluted EPS change of 10.49% versus flat Biotechnology. Walter Schloss would verify quality.
2.21%
Share count reduction below 50% of Biotechnology median of 0.19%. Jim Chanos would check for issues.
No Data
No Data available this quarter, please select a different quarter.